News & Videos - PROTEOMICS INTERNATIONAL LABORATORIES L - English

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to confirm the successful collaboration with Curtin University's Centre for Crop and Disease Management (CCDM), with researchers making an important breakthrough in understanding how dieback impacts plants. - Proteomics International and Curtin University's Centre for Crop and Disease Management collaborate to improve understanding of how dieback impacts plants -...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to provide the following update on its business activities for the three months to 31 March 2024. Key Highlights - Institutional Placement raises A$6.5m: Placement to new and existing institutional investors added global reach to the share register and strengthened Company balance sheet - Update on commercialisation of PromarkerD in the USA: Work is continuing...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to Jefferies Institutional Clients on 28 March 2024. To view the Presentation, please visit: https://abnnewswire.net/lnk/F3W451TE About Proteomics International Laboratories Ltd: Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce it has signed a Material Transfer Agreement with the globally-respected University of Oxford to acquire approximately 600 patient plasma samples for its endometriosis study. - Proteomics International signs Material Transfer Agreement with the University of Oxford to acquire 600 clinical samples for its endometriosis study - Samples will be used for...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ) continues to work diligently toward a national launch in the United States of America, of PromarkerD, the Company's innovative predictive test for diabetic kidney disease, and also advancing the development of its rich pipeline of diagnostic tests for other chronic diseases. Proteomics International advises that, based on its latest assessment of the necessary technical and commercial work required to launch...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce that is has successfully retained its ISO 13485 certification, an internationally recognised standard for safety and quality management systems in the manufacture of medical devices. Recertification will benefit future global sales of the PromarkerD test for diabetic kidney disease and its strong pipeline of innovative diagnostic tests under...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce that its subsidiary OxiDx Pty Ltd, has been granted a patent in 19 major European countries for its platform technology to measure oxidative stress. - The OxiDx technology has been granted a European patent, greatly expanding the intellectual property protection coverage of this unique diagnostic test - OxiDx's novel technology offers a comprehensive...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at Euroz Hartleys Healthcare Forum being held on 6 February 2024. *To view the presentation, please visit: https://abnnewswire.net/lnk/354473MX About Proteomics International Laboratories Ltd: Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce a milestone for its novel blood test for endometriosis, PromarkerEndo, with the clinical validation of the biomarker panel in an independent patient group. The results are being presented at the 29th Annual Lorne Proteomics Symposium, the annual conference of the Australasian Proteomics Society, held 31 January - 3 February 2024. - Proteomics...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce a milestone for its novel blood test for oesophageal adenocarcinoma, PromarkerEso, with the clinical validation of the biomarker panel in a second independent patient group. - Proteomics International's novel PromarkerEso blood test for oesophageal adenocarcinoma advances with biomarker panel clinically validated in second independent patient group -...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ), a medical technology company at the forefront of precision medicine and predictive diagnostics, is pleased to provide the following update on its business activities for the three months to 31 December 2023 and subsequent to the period end. - US Medicare confirms reimbursement price for PromarkerD: Major milestone achieved with Proteomics International's predictive test for diabetic kidney disease assigned a...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce that it has received firm commitments from new and existing institutional investors for a non-underwritten placement of 8.6 million new fully paid ordinary shares ("New Shares") at A$0.76 per New Share ("Placement Price") to raise A$6.5 million in gross proceeds ("Placement"). The issue price of A$0.76 is at a 11.5% discount to the five-day volume...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce the signing of a licence agreement to expand PromarkerD's reach in Central and South America. The deal with long-standing partner Omics Global Solutions (Omics) will see the predictive test for diabetic kidney disease made available in the Republic of Chile, which is home to 1.7 million adults with diabetes. - Proteomics International has signed a licence agreement for the sale of the...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the Chairman's Address provided by Mr Neville Gardiner and the Investor Presentation provided by Dr Richard Lipscombe to shareholders at the Annual General Meeting. *To view the Presentation, please visit: https://abnnewswire.net/lnk/F0Y84N15 About Proteomics International Laboratories Ltd: Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that the US Centers for Medicare & Medicaid Services (CMS) has published its final determination of the national reimbursement price in the United States for the PromarkerD predictive test for diabetic kidney disease. The CMS is the federal agency in the United States that is responsible for providing health coverage to more than 100 million Americans through Medicare and Medicaid. The...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to provide an opportunity for shareholders and investors to view a virtual presentation by Managing Director Dr Richard Lipscombe who will present at the Bell Potter Healthcare Conference 2023. Event: Bell Potter Healthcare Conference Date: Tuesday - Thursday, 14 - 16 November 2023 Format: Webinar Register: Investors wishing to view the presentation must register before 5pm (EST), 13 November here:...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of its latest investor presentation for a non-deal roadshow to institutional investors. *To view the Presentation, please visit: https://abnnewswire.net/lnk/TW664LWM About Proteomics International Laboratories Ltd: Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ), a medical technology company at the forefront of precision medicine and predictive diagnostics, is pleased to provide the following update on its business activities for the three months to 30 September 2023 and subsequent to the period end. - US Medicare sets reimbursement price for PromarkerD and Australian regulatory decision: Major commercial milestone achieved with the diabetic kidney disease (DKD) test...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce its latest results for its novel blood test for oesophageal adenocarcinoma will be presented tomorrow at the 19th ISDE World Congress for Esophageal Diseases in Toronto, Canada, held 8-10 September 2023. - Proteomics International's new PromarkerEso blood test shows strong discrimination of oesophageal cancer - Test targets both oesophageal adenocarcinoma and patients with pre-malignant...

Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that its subsidiary OxiDx Pty Ltd (OxiDx; the Company) has been granted a patent in Japan for its platform technology to measure oxidative stress. The patent marks the first of a new family of patents for OxiDx's next generation diagnostics technology and is another illustration of Proteomics International's specialist platform technologies. - First of a new family of patents for the...